CPC C07K 16/244 (2013.01) [A61P 17/00 (2018.01); A61P 35/00 (2018.01); A61P 37/00 (2018.01); G01N 33/6869 (2013.01); A61K 2039/505 (2013.01); A61K 2039/552 (2013.01); C07K 2317/24 (2013.01); C07K 2317/33 (2013.01); C07K 2317/34 (2013.01); C07K 2317/76 (2013.01); C07K 2317/92 (2013.01); G01N 2333/54 (2013.01)] | 6 Claims |
1. An anti-IL31 antibody, which is a variant of a parent antibody, the parent antibody comprising:
a VH-CDR1 comprising the amino acid sequence set forth in SEQ ID NO: 19, a VH-CDR2 comprising the amino acid sequence set forth in SEQ ID NO: 20, a VH-CDR3 comprising the amino acid sequence set forth in SEQ ID NO: 21, a VL-CDR1 comprising the amino acid sequence set forth in SEQ ID NO: 22, a VL-CDR2 comprising the amino acid sequence set forth in SEQ ID NO: 23, and a VL-CDR3 comprising the amino acid sequence set forth in SEQ ID NO: 24, wherein the variant antibody is selected from a) a variant wherein the Alanine (A) at position 14 of SEQ ID NO: 20 of the parent antibody is substituted with a Serine (S); or b) a variant wherein the Serine (S) at position 5 of SEQ ID NO: 19 of the parent antibody is substituted with an Asparagine (N) and the Alanine (A) at position 14 of SEQ ID NO: 20 of the parent antibody is substituted with a Serine (S).
|